Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00752102 · ClinicalTrials.gov registry record · Phase 4

Vitamin D and Coronary Calcification Study

A Phase 4 study, sponsored by Joslin Diabetes Center.

Completed
Registry status
Phase 4
Development phase
44
Enrollment target

NCT00752102 is a Phase 4 study that has completed, run by Joslin Diabetes Center. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00752102, a Phase 4 study, has completed, sponsored by Joslin Diabetes Center.

COMPLETED
Registry status
Phase 4
Development phase
44 participants
Enrollment target

Study Summary

Patients with chronic kidney disease (CKD) have a higher mortality rate than the general population, with cardiovascular disease (CVD) accounting for approximately 50% of deaths. Vascular calcification is a common finding in patients with CKD. Furthermore, patients with CKD develop secondary hyperparathyroidism, partly because of a decrease of calcitriol synthesis on the kidney. Treatment of secondary hyperparathyroidism includes use of activated vitamin D including calcitriol and paricalcitol. Recent evidence in dialysis patients suggest an improved survival in patients using paricalcitol compared to calcitriol. Studies in uremic rats suggests that there are differential effects of calcitriol and paricalcitol in expression of markers of soft-tissue calcification independent of calcium-phosphorus product. Calcitriol increased calcification of vascular smooth muscle cells cultured in calcification media. There was also significant increase in pulse pressure in animals treated with calcitriol. The investigators hypothesize that these different forms of vitamin D may have differential effects in vascular calcification progression in CKD patients.

Interventions

  • DRUG Paricalcitol
  • DRUG Calcitriol (Rocaltrol®)

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2008-09
Est. Completion 2013-10
Phase Phase 4

Sponsor

Joslin Diabetes Center

73 total trials

What the Registry Record Tells You About NCT00752102

The ClinicalTrials.gov registry entry for NCT00752102 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Paricalcitol is the first listed.

NCT00752102 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00752102 about?

NCT00752102 is a clinical study titled "Vitamin D and Coronary Calcification Study". Patients with chronic kidney disease (CKD) have a higher mortality rate than the general population, with cardiovascular disease (CVD) accounting for approximately 50% of deaths. Vascular calcification is a common finding in patients with CKD. Furthermore, patients with CKD develop secondary hyperpa...

What is the current status of trial NCT00752102?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2008-09. Estimated completion is 2013-10.

What interventions are being tested in trial NCT00752102?

The interventions under investigation include: Paricalcitol (DRUG), Calcitriol (Rocaltrol®) (DRUG).

Who is sponsoring clinical trial NCT00752102?

This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.